Daniel Landi
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma (NCT03299309) | Daniel Landi | 2018-06-29 |
| EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (NCT02664363) | Daniel Landi | 2017-02-01 |
Track Daniel Landi automatically
Every clearance here is in the API, with alerts when new ones post.